Form 4: Neogenomics CFO, Jeffrey Scott Sherman, Reports Stock Transactions

Neogenomics' Chief Financial Officer, Jeffrey Scott Sherman, surrendered 11,746 shares to cover tax obligations related to vesting restricted stock, while also holding various stock options and restricted stock units.

Summary

• Jeffrey Scott Sherman, the Chief Financial Officer of Neogenomics, Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 7, 2024, Mr. Sherman surrendered 11,746 common shares to cover tax obligations related to the vesting of restricted stock.
• Following this transaction, Mr. Sherman directly owns 123,754 common shares.
• Mr. Sherman also holds various stock options, restricted stock units, and performance stock units, which vest over time and are subject to certain performance criteria.
• These holdings include options to purchase 249,169 shares at $11.62, 73,016 shares at $19.65, and 77,913 shares at $16.45.
• He also holds 26,011 restricted stock units, 46,606 restricted stock units, 39,016 performance stock units, and 46,606 performance stock units.
• The performance stock units vest based on share growth and revenue growth goals.

Sentiment

Score: 7

Explanation: The document is a routine filing and does not contain any significant positive or negative news. It provides transparency into executive compensation, which is generally viewed positively.

Positives

• The document provides transparency into the stock holdings of a key executive.
• The vesting schedules of the stock options and units are clearly outlined.

Risks

• The vesting of performance stock units is contingent on the company achieving certain share growth and revenue growth goals, which may not be met.
• The value of the stock options and units is subject to market fluctuations.

Future Outlook

The document does not contain any forward-looking statements about the company's future performance, but it does outline the vesting schedules and performance criteria for Mr. Sherman's stock-based compensation.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the compensation structure and ownership of key executives.

Comparison to Industry Standards

• Stock-based compensation is a common practice for executives in publicly traded companies, particularly in the biotech and healthcare sectors.
• The vesting schedules and performance criteria outlined in the document are typical for executive compensation packages.
• Companies like Exact Sciences, Guardant Health, and Invitae also use stock options and restricted stock units as part of their executive compensation plans.

Stakeholder Impact

• The document provides transparency to shareholders regarding executive compensation.
• The vesting of performance stock units aligns executive interests with shareholder interests.

Key Dates

Keywords

Neogenomics, stock options, restricted stock units, performance stock units, insider trading, Form 4, executive compensation, share ownership, Jeffrey Scott Sherman, CFO